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Post-translational modifications, such as acetylation,
dynamically modulate the chemical and structural prop-
erties of proteins generating new protein-protein inter-
faces. HIV-1 integrase is acetylated by p300 at three
specific lysines located in the carboxy terminal domain. In
the attempt to understand how acetylation modifies the
integration event, we have searched for cellular cofactors
that may specifically require acetylation to bind integrase.
To this aim a tethered catalysis system has been exploited
to perform a yeast two-hybrid screening. In this assay an
integrase constitutively acetylated by fusion with the HAT
catalytic domain of p300, was used as a ''bait'' to screen a
human T-cell cDNA library. One of the identified binding
factors was KAP1, which showed a higher affinity to inte-
grase following its acetylation. This affinity was confirmed
by either pull down assays and in vivo co-immunoprecita-
tion in 293T cells. To evaluate the role of KAP1 during
HIV-1 life cycle, infections were performed in HeLa and
293T cells transiently and stably silenced for KAP1. Inter-
estingly, the infectivity was 3-10 fold higher than control
cells and the analysis of the DNA forms showed a specific
enhancement at the level of integration. In a reciprocal
experiment overexpression of KAP1 showed a reduction
of infectivity by a 50% decrease in integration.
Since integrase activity is positively regulated by acetyla-
tion, we then performed experiments to explore whether
KAP1 inhibition of viral integration might correlate with
modulation of integrase acetylation levels. We demon-
strated that KAP1 binding to acetylated integrase indeed
induces integrase deacetylation through HDAC1 complex
formation. Finally, HDAC1 complex formation is a
requirement for KAP1 viral inhibition since no HIV-1
restriction can be observed in cell silenced for HDAC1.
In conclusion, this study reports that KAP1, recently
described to restrict M-MLV infectivity in embryonic stem
cells at the level of viral transcription, inhibits HIV-1
through a novel mechanism targeting the integration step.
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